🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against superbug strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting over 82 million instances per year. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization marks a significant shift in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

According to data detailed in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which involves a dual-drug approach. The study involved nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in many regions with limited resources.

Clinicians directly involved have voiced positive views. Having a single-dose, oral treatment like this is seen as a "game-changer" for managing the epidemic. This is considered crucial to alleviate the strain of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.